Navigation Links
Dialysis Corporation of America Announces Establishment of Clinical Grant Agreement with the University of Cincinnati, College of Medicine
Date:4/8/2009

LINTHICUM, Md., April 8 /PRNewswire-FirstCall/ -- Dialysis Corporation of America (Nasdaq: DCAI) announced today that it has entered into a grant agreement with the University of Cincinnati, College of Medicine.

The grant, which will total $265,000 each year, for the next three years, will be used solely to support and conduct basic and clinical research relating to kidney disease. This multi-year agreement gives Dialysis Corporation of America a platform from which to support consistent education and innovation in the areas surrounding kidney disease.

"DCA is dedicated to the advancement of kidney disease research, education and patient care," stated company President and CEO, Stephen Everett. "Formalizing this relationship with the University of Cincinnati allows Dialysis Corporation of America to support kidney disease research and education in a comprehensive way while working with an organization dedicated to its mission, independence, and integrity. University of Cincinnati's history of research and education makes this an excellent choice."

Under the agreement Dialysis Corporation of America will provide the University with the amounts due under the grant at the end of the first quarter of each of the three years of the agreement. The initial $265,000 grant amount was provided to the University on March 31st of this year.

Dialysis Corporation of America owns and operates freestanding kidney hemodialysis centers located in Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina, and Virginia, and provides in-hospital dialysis services on a contract basis to certain hospitals located in those states. The company provides patients with their choice of a full range of quality in-center, acute or at-home hemodialysis services.

This release contains forward-looking statements that are subject to risks and uncertainties that could affect the business and prospects of the company and cause actual results and plans to differ materially from those anticipated. Those factors include, but are not limited to, increases in interest rates, the possible need for and availability of additional financing, the company's satisfying the covenants and conditions of its credit facility, certain delays beyond the company's control with respect to future business events, the highly competitive environment in the establishment and operation of dialysis centers, the ability to develop or acquire additional dialysis facilities, whether patient bases of the company's dialysis facilities can mature to provide profitability, the extensive regulation of dialysis operations, government rate determination for Medicare reimbursement, pricing pressure from private payors, and other risks detailed in the company's filings with the SEC, particularly as described in the company's annual report on Form 10-K for the fiscal year ended December 31, 2008. The historical results contained in this press release are not necessarily indicative of future performance of the company.

Other Dialysis Corporation of America press releases, corporate profile, corporate governance materials, quarterly and current reports, and other filings with the Securities and Exchange Commission are available on Dialysis Corporation of America's internet home page: http://www.dialysiscorporation.com.


'/>"/>
SOURCE Dialysis Corporation of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DaVitas IMPACT Program Reduces Mortality for New Dialysis Patients
2. Anti-microbial catheter to cut infection risk for dialysis patients
3. Dialysis Via Fistulas May Help Young or Old
4. NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year
5. Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results
6. Satellite Healthcare Researchers to Present at 29th Annual Dialysis Conference
7. Lowering BP in Dialysis Cases Cuts Heart Risks
8. Preparing for the Next Disaster: Dialysis Community Briefs Hill About Emergency Response
9. High-flux hemodialysis prolongs survival in many patients with CKD
10. Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date
11. B. Braun Wins Premier Contract for Full Line of Dialysis Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America (MOAA) announced ... Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the ... an intimacy with the issues and challenges veterans face with the VA. Following a ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... Santa Monica, CA (PRWEB) , ... June 23, 2017 , ... ... PureLife as the endorsed amalgam separator supplier for CDA members. As part of the ... a reduced price of $99, saving more than $400 off the retail value. This ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: